IDH1 and astrocytoma (excluding glioblastoma): Based on the recognition of IDH mutations as key disease-defining features of astrocytomas and oligodendrogliomas that reliably distinguish them from glioblastomas, assessment of the IDH status has become an integral part of the diagnostic algorithm for glioma classification.